Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 17/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.56 |
| ▸ | PRKDC | P78527 | 1/20 | 0.56 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL189118 | 0.85 | PIK3CG (0.57) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL190084 | 0.85 | PIK3CG (0.57) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL12364310 | 0.84 | PIK3CG (0.58) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL3690862 | 0.82 | PIK3CG (0.60) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188717 | 0.82 | PIK3CG (0.60) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188801 | 0.82 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL189363 | 0.82 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188800 | 0.82 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL2279869 | 0.81 | PIK3CG (0.54) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188716 | 0.81 | PIK3CG (0.78) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |